Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he delves into pivotal studies such as CheckMate 914 Part B and KEYNOTE-564, exploring their implications for kidney cancer. The episode further unravels the transformative findings from the AMBASSADOR study, shedding light on adjuvant immunotherapy in bladder cancer; genetic testing and FGFR advancements in bladder cancer; life-prolonging therapies and radioligand therapies in castration-resistant prostate cancer; and the latest in minimal residual disease research.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA